Biomaterials and Oral Biology Department, School of Dentistry, University of São Paulo, Av. Prof. Lineu Prestes, 2227, Cidade Universitária, 05508-000, São Paulo, SP, Brazil.
São Paulo State University Faculty of Agricultural and Veterinary Sciences, Sao Paulo, Brazil.
Photodiagnosis Photodyn Ther. 2024 Aug;48:104248. doi: 10.1016/j.pdpdt.2024.104248. Epub 2024 Jun 27.
Photobiomodulation therapy (PBMT) has been employed for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing treatment. However, information about the survival of patients receiving PBMT is still lacking. Therefore, the aim of this study was to correlate the survival of patients who either received or did not receive PBMT, combined with cancer treatments, and to assess whether the number of PBMT sessions had a positive impact on survival.
The records of 751 patients seen at Hospital de Caridade São Vicente de Paulo diagnosed with head and neck cancer, treated by D.L.P., the sole operator of PBMT, between 2000 and 2016, were analyzed. The median survival rates were compared by analyzing diagnostic staging, the combination of cancer treatments, and the number of PBMT sessions. Correlation analyses were performed to assess the interactions between the number of PBMT sessions and survival.
PBMT increased survival by 55.14 %, from 1.07 (Without PBMT) to 1.66 years (With PBMT) for the total population and more significantly in Group 41 (stages III and IV, radiation therapy/chemotherapy, with more than five PBMT sessions), the median survival value of 1.83 years, which represents a 66.36 % higher survival rate. In all the analyzed populations, the larger number of sessions was associated with better survival. In terms of survival, advanced stages III and IV almost equated with stages I and II in the absence of PBMT.
PBMT seems to interfere with the survival of patients with head and neck cancer, corroborating its recommendation for the treatment of mucositis, but further research is needed to investigate possible synergistic effects between PBMT and cancer treatments.
光生物调节疗法（PBMT）已被用于预防和治疗头颈部癌症患者在治疗过程中的口腔黏膜炎。然而，关于接受 PBMT 治疗的患者的生存信息仍然缺乏。因此，本研究旨在探讨接受或未接受 PBMT 联合癌症治疗的患者的生存情况，并评估 PBMT 治疗次数是否对生存有积极影响。
分析了 2000 年至 2016 年间在 Hospital de Caridade São Vicente de Paulo 就诊的 751 例头颈部癌症患者的记录，这些患者均由 D.L.P. 进行治疗，他是 PBMT 的唯一操作者。通过分析诊断分期、癌症治疗的联合应用以及 PBMT 治疗次数来比较中位生存时间。进行相关性分析以评估 PBMT 治疗次数与生存之间的相互作用。
PBMT 使总人群的生存率提高了 55.14%，从无 PBMT 的 1.07 年增加到 1.66 年（有 PBMT），在 41 组（III 期和 IV 期、放化疗、接受超过 5 次 PBMT）中更为显著，中位生存值为 1.83 年，生存率提高了 66.36%。在所有分析的人群中，接受 PBMT 治疗的次数越多，生存情况越好。在生存方面，无 PBMT 时，III 期和 IV 期的晚期与 I 期和 II 期几乎等同。
PBMT 似乎会影响头颈部癌症患者的生存情况，这支持了将其推荐用于治疗黏膜炎的建议，但需要进一步研究以调查 PBMT 和癌症治疗之间可能的协同作用。
